STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript

Despite a 9% year-over-year revenue decline to $7.7 million and an adjusted EBITDA loss of $762,000 in Q2 2025, largely impacted by international trade disruptions and increased litigation-related operating expenses, STRATA Skin Sciences (SSKN) is poised for significant future growth. The company highlighted the American Medical Association's recent expansion of CPT codes for its XTRAC 308-nanometer excimer laser, effective January 2027, to include approximately 30 inflammatory and autoimmune skin conditions, which triples its total addressable market to 30 million patients. SSKN is actively pursuing temporary G codes to accelerate reimbursement eligibility to 2026 and seeking increased reimbursement rates, while also strengthening its legal position in an ongoing lawsuit against LaserOptek for false marketing.

Analysis

STRATA Skin Sciences (SSKN) reported a challenging second quarter for 2025, with total revenue declining 9% year-over-year to $7.7 million and an adjusted EBITDA loss of $762,000. The weakness was primarily driven by a 15% decline in international revenue to $2.6 million, attributed to trade disruptions in China and distributor issues in Korea, which also contributed to an 18% drop in equipment sales. Domestically, XTRAC recurring billings saw a modest 2% decline to $4.7 million. Profitability was further pressured by increased operating expenses, which rose to $6.5 million from $5.5 million in the prior year, partly due to $340,000 in litigation costs against competitor LaserOptek. Despite these headwinds, the core investment thesis is centered on a significant future catalyst: the AMA's expansion of CPT codes for the XTRAC laser. This regulatory change, set for January 2027, will cover approximately 30 new indications beyond psoriasis, such as vitiligo and atopic dermatitis, effectively tripling the total addressable market to 30 million patients. The company is actively pursuing temporary G codes with CMS to potentially accelerate this opportunity to 2026 and is also submitting data to support an increase in reimbursement rates. This potential dual expansion of patient volume and revenue per procedure, supported by new clinical data and patents for combination therapies, represents a transformational inflection point, though it is contingent on future regulatory success.

Key Decisions for Investors

• Investors should closely monitor communications regarding the company's application for temporary G codes, as securing them for 2026 would significantly accelerate the revenue potential from the expanded CPT codes and is the primary near-term catalyst.
• The current investment thesis requires tolerating near-term financial weakness, including declining revenues and an EBITDA loss, for the prospect of significant, long-term growth contingent on the successful implementation of new reimbursement frameworks.
• Monitor the impact of tariffs on the international business, which remains a key risk to revenue guidance, and track developments in the LaserOptek litigation as it represents both a current cash drain and a potential source of significant future damages.
• Given the quarterly cash usage of $1.9 million against a $6.0 million cash balance, assess the company's liquidity runway and potential need for future financing to bridge operations until the expanded reimbursement catalysts can materialize.